Emergency Department, Baystate Medical Center, Springfield, MA, United States.
Physiology Department, Georgetown University, Washington, United States.
Expert Opin Pharmacother. 2020 Mar;21(4):409-415. doi: 10.1080/14656566.2019.1703951. Epub 2020 Jan 11.
: Dyspareunia caused by vulvovaginal atrophy is a primary symptom of genitourinary syndrome of menopause (GSM), a chronic, progressive medical condition that results from estrogen and androgen deficiency at menopause. Dehydroepiandrosterone (DHEA, prasterone) is an endogenous precursor steroid hormone that is metabolized into both androgens and estrogens that has been recently been approved by the FDA for the treatment of moderate to severe dyspareunia caused by vulvovaginal atrophy secondary to menopause.: This is a comprehensive drug evaluation describing the chemical composition, pharmacokinetics, metabolism, clinical efficacy and safety of dehydroepiandrosterone (prasterone) in the treatment of dyspareunia and VVA secondary to menopause. Preclinical and clinical data suggesting further potential uses, benefits, and contraindications in the genitourinary health of postmenopausal women are also considered.: Intravaginal dehydroepiandrosterone (prasterone) is effective for the management of dyspareunia secondary to menopause and may be effective in the treatment of other types of sexual dysfunction that are secondary to menopause. Further studies should explore additional dosing regimens and different indications.
: 绝经后女性因外阴阴道萎缩导致的性交困难是女性生殖泌尿系统绝经后综合症状（GSM）的主要症状，GSM 是一种慢性、进行性疾病，由绝经后雌激素和雄激素缺乏引起。脱氢表雄酮（DHEA，普拉睾酮）是一种内源性前体甾体激素，可代谢为雄激素和雌激素，最近已被 FDA 批准用于治疗绝经后因外阴阴道萎缩引起的中重度性交困难。: 这是一份全面的药物评估报告，描述了脱氢表雄酮（普拉睾酮）治疗绝经后因性交困难和 VVA 引起的外阴阴道萎缩的化学组成、药代动力学、代谢、临床疗效和安全性。还考虑了提示其在绝经后女性生殖健康方面有进一步潜在用途、益处和禁忌症的临床前和临床数据。: 阴道内给予脱氢表雄酮（普拉睾酮）对治疗绝经后性交困难有效，可能对治疗其他绝经后引起的性功能障碍也有效。应进一步研究探索其他剂量方案和不同的适应证。
